Mollie Cotty, NP
Primary Care · Columbia, SCNPI 1093141004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $766 and has fallen 71.4% since, to $219 in 2025.
Across 103 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$389
- Abbott$205
- Dexcom, Inc.$190
- Lilly USA, LLC$155
- Novo Nordisk$150
- GSK$83
- plus $594 from 18 others
What the payments were for
- Food & beverage$1,767100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $389 |
| Abbott | 7 | $205 |
| Dexcom, Inc. | 6 | $190 |
| Lilly USA, LLC | 10 | $155 |
| Novo Nordisk | 7 | $150 |
| GSK | 5 | $83 |
| Daiichi Sankyo Inc. | 4 | $83 |
| AstraZeneca | 6 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $69 |
| Bayer | 4 | $66 |
| Pfizer | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Novartis | 1 | $23 |
| Amgen | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $18 |
| Inari Medical, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Merck | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$1,767 in reported general payments places this provider in the 70th percentile of 115 primary care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $520 |
| Amlodipine Besylate | 71 | $405 |
| Duloxetine Hcl | 20 | $397 |
| Doxycycline Hyclate | 45 | $373 |
| Losartan Potassium | 32 | $363 |
| Rosuvastatin Calcium | 33 | $359 |
| Bupropion XlBupropion Hcl | 17 | $343 |
| Pantoprazole Sodium | 17 | $312 |
| Levothyroxine Sodium | 31 | $291 |
| Atorvastatin Calcium | 46 | $261 |
| Famotidine | 25 | $255 |
| Lisinopril | 30 | $251 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 30 | $247 |
| Escitalopram Oxalate | 31 | $210 |
| Omeprazole | 21 | $184 |
Paid to pharmacies, not to this prescriber.
Other primary care in Columbia
- Patricia HeadColumbia$6K
- Lyndsey MathiasColumbia$3K
- Yolanda Boyd-GanttColumbia$3K
- Madeline SmithColumbia$2K
- Jennifer GillisColumbia$2K
- Marisa GentryColumbia$2K
- Hadyn GauseColumbia$2K
- Adrenna JacksonColumbia$2K
- Deidra WillisColumbia$1K
- Tiffany JohnsonColumbia$787
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.